Aurora Kinases and Their Inhibitors: More Than One Target and One Drug

摘要: Dependent on the degree of inhibition different Aurora kinase family members, various events in mitosis are affected, resulting differential cellular responses. These responses have to be considered clinical development small molecule inhibitors with respect chosen indications, schedules and appropriate endpoints. Here properties most advanced compared a case report PHA-739358 - spectrum selective kinases inhibitor dominant phenotype inhibition, which is currently being tested trials discussed. One selection criteria for this compound was its property inhibiting more than one cancer relevant target, such as Abl wild-type multidrug resistant T315I mutant. This opens another path CML, underway evaluate activity patients suffering from chronic myelogenous leukemia, who developed resistance approved treatments.